Cogent Biosciences, Inc.

COGT · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.4%

Institutions115.0%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	–	–	–	–	$7.87M	$22.50M	$9.73M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$333.36M	-$275.94M	-$147.84M	-$75.55M	-$82.20M	-$32.18M	-$36.01M
Operating income as a percentage of revenue.	–	–	–	–	-1044.3%	-143.0%	-369.9%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$328.94M	-$255.86M	-$140.24M	-$72.27M	-$74.81M	-$31.83M	-$34.55M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-2.16	$-1.94	$-2.39	$-1.87	$-16.17	$-1.00	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-2.16	$-1.94	$-2.39	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$312.01M	$98.17M	$139.89M	$219.68M	$242.19M	$37.42M	$55.67M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$937.61M	$327.90M	$300.81M	$232.09M	–	$49.42M	$85.93M
Everything the company owes — debt, unpaid bills, and other obligations.	$301.24M	$71.61M	$45.08M	$17.91M	–	$17.66M	$25.69M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$636.37M	$256.29M	$255.74M	$214.18M	–	$31.76M	$60.23M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$264.44M	-$207.79M	-$118.64M	-$58.76M	-$35.85M	-$41.51M	-$32.49M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$1.55M	$573000	$6.86M	$1.72M	–	$33000	$549000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$266.00M	-$208.36M	-$125.50M	-$60.48M	–	-$41.55M	-$33.04M

	You	Peer avg
Revenue Growth	–	+43.0%
ROE	-109.7%	-246.0%

Cogent Biosciences, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison